Pattern and Predictors of Immunologic Recovery in Human Immunodeficiency Virus-Infected Children Receiving Non-Nucleoside Reverse Transcriptase Inhibitor-Based Highly Active Antiretroviral Therapy
Authors:
- Thanyawee PuthanakitTPThanyawee Puthanakit
- Stephen J. KerrSKStephen J. Kerr
- Jintanat AnanworanichJAJintanat Ananworanich
- Torsak BunupuradahTBTorsak Bunupuradah
- Pitch BoonrakPBPitch Boonrak
- Virat SirisanthanaVSVirat Sirisanthana
- 1 June 2009
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 28 (6) , 488-492
Abstract
Non-nucleoside reverse transcription inhibitor (NNRTI)-based highly active antiretroviral therapy (HAART) is the recommended first-line regimen for children in Thailand. This study was aimed to assess pattern and predictors of immune recovery in antiretroviral-naive Thai children starting NNRTI-based HAART. Records were extracted from clinical databases of 2 treatment cohorts in Thailand. The inclusion criteria were HIV-infected naive children who initiated NNRTI-based HAART when CD4 <25%. Immune recovery was defined as achieving a target CD4% of 25. The impact of age, gender, baseline clinical category, CD4 and HIV RNA titer, and regimen on immune recovery to weeks 96 was assessed using multiple logistic regression. There were 274 patients (52% females) with a median baseline age of 7 (Interquartile range [IQR]: 4–9) years and a median CD4% of 5 (IQR: 1–12) who started treatment with nevirapine (66%) or efavirenz (34%) based HAART. Median duration of follow-up was 168 (IQR: 120–192) weeks. The median CD4% increase from baseline was 7% (IQR: 5–11) and 18% (IQR: 12–23) at weeks 24 and 96, respectively. The probability of reaching target CD4% was 51% (95% confidence interval: 45%–57%) by week 96. The predictors of immune recovery at week 96 were younger age, female gender, higher baseline CD4%, and sustained virologic suppression after week 24. In this cohort of children with low baseline CD4, half achieved immune recovery after 96 weeks of HAART. The predictors for immune recovery are younger children, female gender, high baseline CD4%, and long-term virologic suppression.Keywords
This publication has 20 references indexed in Scilit:
- Long‐Term Effects of Highly Active Antiretroviral Therapy on CD4+Cell Evolution among Children and Adolescents Infected with HIV: 5 Years and CountingClinical Infectious Diseases, 2008
- Treatment Outcomes Stratified by Baseline Immunological Status among Young Children Receiving Nonnucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Resource-Limited SettingsClinical Infectious Diseases, 2007
- Gender Differences in Survival in an HIV/AIDS Cohort from São Paulo, BrazilAIDS Patient Care and STDs, 2007
- Hospitalization and Mortality among HIV-Infected Children after Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2007
- CD4+ Cell Count 6 Years after Commencement of Highly Active Antiretroviral Therapy in Persons with Sustained Virologic SuppressionClinical Infectious Diseases, 2007
- In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapyAIDS, 2006
- Long-Term Effects of Highly Active Antiretroviral Therapy in Pretreated, Vertically HIV Type 1-Infected Children: 6 Years of Follow-UpClinical Infectious Diseases, 2006
- Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'IvoireAIDS, 2004
- Response to highly active antiretroviral therapy varies with ageAIDS, 2004
- Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and IrelandBMJ, 2003